Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Comment by prokofievon Aug 26, 2018 2:00am
211 Views
Post# 28518252

RE:RE:RE:RE:Holding Pattern

RE:RE:RE:RE:Holding Pattern

Did not mean to mislead anyone with my last post, as I truly believe Helius Medical will file any day now.
 

The meeting with the FDA did happen in early July and they did not require any additional studies. At this point I am pretty sure the submissions are completed and ready to be sent to the regulators in all geographies (management wants to file at the same time). 
 

I am somewhat speculating here, but I have seen this before with another company. There is an administrative follow up required following the meetings with the FDA. Some kind of paperwork has to be completed and sent to FDA, which then has to be acknowledged as received by the regulator before the submission can be sent. With August being the peak season for vacation, I would not be surprised the low staffing levels are leading to this administrative delay.
 

So next 30 days?
 

Submission with the FDA, Health Canada and CE Mark in Europe. This will be press released no doubt about it. 
 

I believe the CEP (Clinical Experience Programs) at the clinics should start any day too. Recall, Helius will be treating patients in a real life setting (no sham/control arm studies) in one of the 5 or 6 CEP clinics (which will be the first to launch the PoNS commercially). The data will be open, and thus Helius, the clinics and the payers groups (insurance/workers comp) will be able to quickly assess how much money will be ultimately saved by treating the patients with the therapy (economic benefit). 
 

Prokofiev

Bullboard Posts